What have been the guiding principles in these achievements and what might the future hold for antiviral drug development? In the late 1970s, the discovery that acyclic nucleoside analogues ...

The first two drugs brought to market for treating COVID-19 were both nucleoside analogs." Meanwell and his team focused their approach on C4ʹ-modified nucleoside analogs, a particular subclass ...

Nucleoside analogues mimic the building blocks of DNA and RNA, allowing them to interfere with viral replication. Prodrugs, on the other hand, are chemically modified drugs that become active only ...

[2] Tenofovir was approved by the Food and Drug Administration (FDA) in October 2001 through an accelerated approval process; it is the first nucleotide analogue reverse-transcriptase inhibitor ...

Typically, producing these analogs is complicated ... platform will serve as a route towards a greater range of nucleoside-based drugs," says Matthew Willmott, Manchester Institute of ...

Well, for starters, interferon [IFN] and nucleoside analogue therapy don't work as well. Not only that, but they are not curative therapies by any means. These available drugs are able to slow or ...

Imbalances in pyrimidine biosynthesis can lead to various disorders, such as orotic aciduria and pyrimidine nucleoside phosphorylase deficiency. Some pyrimidine analogs, such as azidothymidine (AZT) ...